Scarica l'app Stockscreener
0.4973
1.23%
-0.0062
Precedente Chiudi:
$0.5035
Aprire:
$0.49
Volume 24 ore:
252.66K
Relative Volume:
0.14
Capitalizzazione di mercato:
$48.78M
Reddito:
$190.00K
Utile/perdita netta:
$-70.03M
Rapporto P/E:
-0.6772
EPS:
-0.7343
Flusso di cassa netto:
$-59.30M
1 W Prestazione:
-7.91%
1M Prestazione:
-6.03%
6M Prestazione:
-48.44%
1 anno Prestazione:
-90.91%
Intervallo 1D:
$0.4872
$0.508
Intervallo di 1 settimana:
$0.475
$0.5431
Portata 52W:
$0.395
$6.50
Atyr Pharma Inc Stock (ATYR) Company Profile
Nome
Atyr Pharma Inc
Settore
Industria
Telefono
(858) 731-8389
Indirizzo
10240 SORRENTO VALLEY ROAD, SAN DIEGO
Compare ATYR vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ATYR
Atyr Pharma Inc
|
0.4973 | 49.34M | 190.00K | -70.03M | -59.30M | -0.7343 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Atyr Pharma Inc Stock (ATYR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-16 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-09-15 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2025-09-15 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2025-09-15 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2025-09-15 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2025-02-18 | Iniziato | Leerink Partners | Outperform |
| 2025-01-06 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-10-04 | Iniziato | Wells Fargo | Overweight |
| 2024-09-05 | Iniziato | Jefferies | Buy |
| 2023-07-05 | Downgrade | Oppenheimer | Outperform → Perform |
| 2021-10-12 | Iniziato | RBC Capital Mkts | Outperform |
| 2021-09-21 | Iniziato | Piper Sandler | Overweight |
| 2021-05-10 | Iniziato | Laidlaw | Buy |
| 2020-08-17 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2020-03-04 | Iniziato | ROTH Capital | Buy |
| 2020-03-02 | Iniziato | Oppenheimer | Outperform |
| 2018-02-14 | Downgrade | JP Morgan | Neutral → Underweight |
| 2017-09-07 | Iniziato | Piper Jaffray | Overweight |
| 2016-12-13 | Downgrade | JP Morgan | Overweight → Neutral |
| 2015-12-16 | Iniziato | Citigroup | Neutral |
| 2015-06-01 | Iniziato | Citigroup | Buy |
| 2015-06-01 | Iniziato | JP Morgan | Overweight |
Mostra tutto
Atyr Pharma Inc Borsa (ATYR) Ultime notizie
FB: aTyr Pharma shares have over 500% upside as the company prepares a new Phase III - Freedom Broker
aTyr Pharma Company Profile & Introduction - Moomoo
ATYR Q2 2026 Earnings: Narrower-Than-Expected Loss Lifts SharesFree Cash Flow Trends - vinanet.vn
aTyr Pharma(ATYR) Stock Options Chain | Quotes & News - Moomoo
Q3 Earnings Forecast for aTyr Pharma Issued By HC Wainwright - MarketBeat
Layoff Tracker: Aura, Schrödinger trim workforces - BioSpace
Why is aTyr Pharma stock gaining today? By Investing.com - Investing.com India
H.C. Wainwright Maintains ATyr Pharma(ATYR.US) With Hold Rating - moomoo.com
Levi & Korsinsky Urges aTyr (ATYR) Shareholders to Act Before Lead Plaintiff Deadline December 8, 2025 - The National Law Review
Securities Lawsuit Alert: aTyr Pharma, Inc. (ATYR) InvestorsContact Levi & Korsinsky Before December 8, 2025 - The National Law Review
aTyr Pharma Ord Shs (LIFE) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
ATyr Pharma Announces Second Quarter 2026 Res - Moomoo
aTyr Pharma Announces Second Quarter 2026 Results, Program Prioritization and Corporate Restructuring to Support Efzofitimod Program in ILD - The Manila Times
aTyr Pharma Q2 Results: EPS of $(0.11) beats estimates - scanx.trade
ATYR Looks 13.6% Overvalued on GF Value™ as Cash Supports Develo - GuruFocus
ATYR Looks 13.6% Overvalued on GF Value™ as It Restructures Amid Pulmonary Sarcoidosis Focus - GuruFocus
ATyr Pharma Sees Funding Sufficient Into Late 2028 >ATYR - moomoo.com
Class Action Lawsuit Filed: aTyr Pharma, Inc. (ATYR) – Join by December 8, 2025 – Contact Levi & Korsinsky - The National Law Review
ATyr Pharma Fiscal Q2 Loss Narrows; Announces Restructuring Plans - marketscreener.com
Update: ATyr Pharma Fiscal Q2 Loss Narrows; Announces Restructuring Plans - Moomoo
ATyr Pharma Fiscal Q2 Loss Narrows - marketscreener.com
aTyr Pharma cuts 60% of workforce after Q2 results - Quiver Quantitative
Atyr Pharma: Q2 Earnings Snapshot - Barchart.com
aTyr Pharma Inc reports results for the quarter ended June 30Earnings Summary - TradingView
aTyr Pharma Q2 net loss narrows - TradingView
aTYR Pharma posts Q2 2026 net loss of $10.3M, $58.9M cash; prioritizes efzofitimod in ILD - TradingView
aTYR PHARMA INC 2Q 2026: Net loss $(10.3M), EPS $(0.11) — 10-Q Summary - TradingView
aTyr Pharma Prioritizes Efzofitimod Program, Cuts Workforce 60% as FDA Feedback on Phase 3 Sarcoidosis Study Protocol Looms - Quiver Quantitative
ATyr Pharma, Inc. Announces CFO Changes - marketscreener.com
FMR LLC and Abigail Johnson (ATYR) disclose 2.5% ATYR Pharma ownership - Stock Titan
ATYR Q2'26 Earnings: revenue estimate is 0 USD - TradingView
LIFE|aTyr Pharma Ord Shs|Price:22.810|Chg%:+2.390 - tradingkey.com
ATYR Stockholders Have Opportunity to Lead aTyr Pharma, Inc. Clas - The National Law Review
Alerts on Ethos Technologies' Q2 results wrongly attributed to Atyr Pharma withdrawn - marketscreener.com
BRIEF-aTyr Pharma Q2 Net Income USD 19.531 Million - TradingView
aTyr Pharma Inc expected to post a loss of 12 cents a shareEarnings Preview - TradingView
ATYR Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Shares Up 1.19%Earnings Surprise Score - vinanet.vn
aTyr Pharma (ATYR) Rises 1.25% as Shares Defend Key $0.47 Support LevelTrading Ideas - vinanet.vn
LIFE|aTyr Pharma Ord Shs|Price:20.500|Chg%:+0.080 - TradingKey
ATYR Q1 2026 Earnings: Narrowed Loss Beats Expectations Despite No RevenuePerformance Review - Vinanet
I am an 18-year-old ... - marketscreener.com
aTyr Pharma Inc (ATYR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
BlackRock (ATYR holder) reports 1.8% beneficial stake in aTYR PHARMA INC - Stock Titan
ATYR|aTyr Pharma Inc|Price:0.486|Chg%:+0.006 - TradingKey
aTyr Pharma Inc (ATYR) Cash Flow - TradingKey
aTyr Pharma Inc (ATYR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
aTyr Pharma Ord Shs (LIFE) Institutional Confidence - TradingKey
aTyr Pharma Inc (ATYR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
aTyr Pharma (ATYR) Edges Higher Amidst Quiet Trading; Key Resistance in FocusActive ETF Flow - vinanet.vn
aTyr Pharma Inc (ATYR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
aTyr Pharma, Inc. Revenue Breakdown – NASDAQ:ATYR - TradingView
Atyr Pharma Inc Azioni (ATYR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Atyr Pharma Inc Azioni (ATYR) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Shukla Sanjay | President and CEO |
Feb 04 '26 |
Sale |
0.98 |
3,745 |
3,655 |
153,553 |
| Broadfoot Jill Marie | Chief Financial Officer |
Feb 04 '26 |
Sale |
0.98 |
1,558 |
1,521 |
37,296 |
| DENYES NANCY | General Counsel |
Feb 04 '26 |
Sale |
0.98 |
1,118 |
1,091 |
33,124 |
| SCHIMMEL PAUL | Director |
Oct 08 '25 |
Buy |
0.90 |
682,001 |
612,437 |
1,095,024 |
| SCHIMMEL PAUL | Director |
Oct 09 '25 |
Buy |
0.94 |
317,999 |
299,364 |
1,413,023 |
0.86%
0.31%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):